LTB

• Description :

  LTB is a prodrug formed by coupling glycolysis inhibitor (Lonidamine (HY-B0486) ) with PD1/PDL1 blocker (BMS-1 (HY-19991) ) by thioketal linkage. LTB can further encapsulate photosensitizer chlorine e6 (Ce6) (HY-13594) to construct a co-delivery photodynamic nanoplatform (LTB-6 NPs) by self-assembly[1].

• Product Name Alternative :

  Lon-TK-BMS-1

• UNSPSC :

  12352005

• Target :

  PD-1/PD-L1

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ltb.html

• Smiles :

  COC1=CC(OCC2=C(C(C3=CC=CC=C3)=CC=C2)C)=CC(OC)=C1CN4CCCC[C@H]4C(OCCCSC(C)(SCCCOC(C5=NN(C6=C5C=CC=C6)CC7=CC=C(C=C7Cl)Cl)=O)C)=O

• Molecular Formula :

  C53H59Cl2N3O7S2

• Molecular Weight :

  985.09

• References & Citations :

  [1]Zhang Y, et al. Novel co-delivery nanomedicine for photodynamic enlarged immunotherapy by cascade immune activation and efficient Immunosuppression reversion. Bioorg Chem. 2024 Dec;153:107978.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported